Clinical Trials Logo

Advanced Malignancies clinical trials

View clinical trials related to Advanced Malignancies.

Filter by:

NCT ID: NCT06206915 Not yet recruiting - Clinical trials for Advanced Malignancies

Phase I Study of XZ120 in Malignant Tumors

Start date: February 1, 2024
Phase: Phase 1
Study type: Interventional

This research includes two parts: the first part of the patients with late malignant tumor monotherapy study, at the beginning of the second part in treat DLBCL and research on combination therapy in patients with advanced breast cancer. Research purpose: to evaluate XZ120 safety, tolerability, for the treatment of malignant tumor patients pharmacokinetic characteristics and preliminary effectiveness.

NCT ID: NCT06202261 Recruiting - Clinical trials for Metastatic Breast Cancer

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

Start date: April 13, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase Ib/II exploratory study. Phase Ib includes the dose escalation and expansion study of monotherapy, as well as the dose escalation study of combination therapy. After determining the maximum tolerated dose (MTD), a dose expansion study is conducted to observe the safety and efficacy in monotherapy. Phase II study is to further observe the safety and efficacy of TQB2930 combined with albumin-paclitaxel (cohort 3), or chemotherapy selected by investigators (cohort 4).

NCT ID: NCT06038058 Not yet recruiting - Clinical trials for Advanced Malignancies

A Phase I Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies

Start date: October 2023
Phase: Phase 1
Study type: Interventional

This is a Phase I, multicenter, open-label, single-arm and first-in-human clinical study of BRY812 for injection. The study objectives are to evaluate the safety, tolerability, pharmacokinetic profile, anti-tumor activity and immunogenicity of BRY812 for injection in patients with advanced malignancies. Patients will receive treatment every 3 weeks until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation, or withdrawal from the study.

NCT ID: NCT05987605 Not yet recruiting - Clinical trials for Advanced Malignancies

Clinical Study of 1A46 Drug Substance

Start date: October 1, 2023
Phase: Phase 1
Study type: Interventional

A phase I/II, first in human, single arm, open label study to evaluate the safety and efficacy of the injection of triple-specific T-cell engager 1A46 in adult subjects with R/R CD20 positive and/or CD19 positive B cell non-Hodgkin's lymphoma (B - NHL)

NCT ID: NCT05891171 Recruiting - Ovarian Cancer Clinical Trials

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

ARC-25
Start date: October 13, 2023
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to assess the safety and tolerability of AB598 when taken alone, and in combination with zimberelimab and standard chemotherapy in participants with advanced malignancies.

NCT ID: NCT05577182 Recruiting - Clinical trials for Advanced Malignancies

Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies

Start date: November 14, 2022
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, single-arm study to investigate the safety, tolerability, PK, pharmacodynamics and preliminary activity of INCA32459 in participants with selected advanced malignancies. Part 1 (dose escalation) will determine the recommended dose of INCA 32459 for expansion (RDE) and the maximum tolerated dose (MTD). Part 2 (dose expansion) will further evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of INCA 32459 at the recommended dose(s) for expansion in 2 tumor-specific cohorts.

NCT ID: NCT05391022 Completed - Solid Tumor Clinical Trials

Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies

Start date: July 20, 2021
Phase: Phase 1
Study type: Interventional

Phase 1 2-part study to evaluate the effect of food on pharmacokinetics of pelabresib (CPI-0610) and the effect of pelabresib on QTc in patients with advanced malignancies

NCT ID: NCT05359692 Withdrawn - Clinical trials for Advanced Malignancies

INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, efficacy, PK and pharmacodynamics of INCAGN01876 when given in combination with retifanlimab. The study will consist of 2 parts: a safety lead-in part (Part 1) followed by a dose expansion part (Part 2).

NCT ID: NCT05351697 Not yet recruiting - Clinical trials for Advanced Malignancies

Phase I Clinical Study of BR105 Injection

BR105-I
Start date: April 2022
Phase: Phase 1
Study type: Interventional

A phase 1, dose escalation and dose expansion study of BR105 in patients with advanced malignancies.

NCT ID: NCT05245916 Withdrawn - Clinical trials for Advanced Malignancies

IBI397 or Combination Therapies in Patients With Advanced Malignancies

Start date: April 14, 2022
Phase: Phase 1
Study type: Interventional

The primary objective of this phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBI397 or its Combination Therapies in Patients with Advanced Malignancies